Jiutian Chemical Group Limited: Q3 2025 Financial Performance – Detailed Investor Update

Key Highlights

• Revenue Surges: The Group reported revenue of RMB 2.8 million for Q3 2025, marking an impressive 217% increase compared to RMB 0.89 million in Q3 2024. This significant uptick was primarily fueled by higher revenue from chemical trading activities.
• Production Strategy: Despite the revenue increase, total revenue levels remained low because management strategically halted the production of DMF and Methylamine in Q3 2025 and Q2 2024, respectively. This prudent move aimed to minimize losses during market downturns and allowed the Group to fine-tune manufacturing processes for improved operational efficiency.
• Narrowed Net Loss: The Group recorded a net loss attributable to shareholders of RMB 30.34 million in Q3 2025—an improvement from a RMB 36.91 million net loss in Q3 2024. This reduction reflects successful cost-control efforts and the impact of the temporary production halt.
• Gross Loss Improvement: Gross loss narrowed from RMB 16.5 million in Q3 2024 to RMB 15.1 million in Q3 2025, a 9% improvement, signifying better cost management despite the tough operating environment.
• Accounting Adjustment: The reported figures for Q3 2024 have been restated following the FY2024 audit. The Group was determined to be acting as a distribution agent in certain trading transactions; hence, revenue, cost of sales, and other income are now recognized on a net basis, impacting comparative results.

Financial Position

• Current Assets: RMB 428.2 million as of 30 September 2025, down from RMB 625.6 million at year-end 2024.
• Non-Current Assets: RMB 398 million, down from RMB 420.2 million at year-end 2024.
• Current Liabilities: RMB 220 million, improved from RMB 326.6 million at year-end 2024.
• Non-Current Liabilities: RMB 83.3 million, reduced from RMB 101.3 million at year-end 2024.
• Net Assets: RMB 523 million, down from RMB 618 million at year-end 2024.
• Shareholder Equity: Remained stable at RMB 710 million in share capital and RMB 111 million in reserve fund, but accumulated losses widened from RMB 203 million to RMB 298 million.

Key Points for Shareholders – Potentially Price Sensitive Information

• Strategic Production Halt: Management’s decision to temporarily halt DMF and Methylamine production is a major operational change. While it helped reduce losses and allowed for process improvements, it also limits top-line growth. Investors should closely monitor when production resumes and how quickly efficiencies translate into stronger results.
• Revenue Model Restatement: The restatement to a net basis for trading revenue, cost of sales, and other income impacts historical comparability. This accounting change could affect the perception of revenue quality and business model risk.
• Improving Loss Trajectory: The narrowing of both gross and net losses signals progress in cost management—even as revenue remains weak. If operational efficiencies continue, the Group could return to profitability when market conditions improve.
• Balance Sheet Movements: Significant reduction in assets and liabilities shows active balance sheet management, but declining net assets and rising accumulated losses are areas of concern for long-term shareholder value.
• Readiness for Recovery: The Group emphasizes its commitment to financial discipline and operational readiness. Investors should watch for announcements about market recovery or resumption of production, which could be catalysts for share price movement.

Outlook

The Group acknowledges that the external environment remains challenging. However, ongoing efforts to enhance operational efficiency and strengthen cost management have made encouraging progress. The Board remains committed to maintaining financial discipline and operational readiness to capture growth opportunities as market conditions improve.

Shareholders should remain alert for further updates, as any material changes in production strategy or market conditions could significantly impact the Group’s financial performance and share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. While the information herein is based on unaudited financial disclosures from Jiutian Chemical Group Limited, future performance is subject to risks and uncertainties, including market conditions and management decisions.

View Jiutian Chemical Historical chart here